Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Innoviva Inc (INVA)

Innoviva Inc (INVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Innoviva Inc 1350 OLD BAYSHORE HIGHWAY SUITE 400 BURLINGAME CA 94010 USA

www.inva.com Employees: 159 P: 650-238-9600

Sector:

Medical

Description:

Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.

Key Statistics

Overview:

Market Capitalization, $K 1,659,998
Enterprise Value, $K 1,366,788
Shares Outstanding, K 74,074
Float, K 72,407
% Float 97.75%
Short Interest, K 6,715
Short Float 8.98%
Days to Cover 7.26
Short Volume Ratio 0.65
% of Insider Shareholders 2.25%
% of Institutional Shareholders 99.12%

Financials:

Annual Sales, $ 411,330 K
Annual Net Income, $ 271,170 K
Last Quarter Sales, $ 114,610 K
Last Quarter Net Income, $ 164,150 K
EBIT, $ 170,220 K
EBITDA, $ 212,340 K

Growth:

1-Year Return 26.55%
3-Year Return 100.45%
5-Year Return 82.79%
5-Year Revenue Growth 22.13%
5-Year Earnings Growth 65.82%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 1.08 on 11/05/25
Next Earnings Date 05/06/26
Earnings Per Share ttm 4.04
EPS Growth vs. Prev Qtr 79.63%
EPS Growth vs. Prev Year 240.35%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Most Recent Dividend 0.250 on 09/08/15
Next Ex-Dividends Date 09/08/15
Dividend Payable Date 09/30/15
Dividend Payout Ratio 0.00%

INVA Ratios

Ratio
Price/Earnings ttm 5.52
Price/Earnings forward 11.22
Price/Earnings to Growth N/A
Return-on-Equity % 37.63%
Return-on-Assets % 23.60%
Profit Margin % 65.93%
Debt/Equity 0.22
Price/Sales 4.02
Price/Cash Flow 4.44
Price/Book 1.42
Book Value/Share 15.71
Interest Coverage 20.57
60-Month Beta 0.42
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar